IGF-I in human growth: Lessons from defects in the GH-IGF-I axis

Nestle Nutrition Institute Workshop Series

Volumn 71, Issue , 2013, Pages 43-55

  Hwa, Vivian ^a   Fang, Peng ^a   Derr, Michael A ^a   Fiegerlova, Eva ^a   Rosenfeld, Ron G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GLYCOPROTEIN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOTROPIN BINDING PROTEIN; SOMATOTROPIN-BINDING PROTEIN; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN;

ARTICLE; CHILD; GENETICS; HUMAN; IMMUNE DEFICIENCY; INSULIN RESISTANCE; INTELLECTUAL IMPAIRMENT; INTRAUTERINE GROWTH RETARDATION; METABOLISM; MICROCEPHALY; MUTATION; PHYSIOLOGY;

CARRIER PROTEINS; CHILD; FETAL GROWTH RETARDATION; GLYCOPROTEINS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; INTELLECTUAL DISABILITY; MICROCEPHALY; MUTATION; RECEPTOR, IGF TYPE 1; STAT5 TRANSCRIPTION FACTOR;

EID: 84886044699     PISSN: 16642147     EISSN: 16642155     Source Type: Book Series    
DOI: 10.1159/000342548     Document Type: Conference Paper

References (42)

1. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. New Engl J Med 1996;335: 1363-1367
2. Walenkamp MJE, Karperien M, Pereira AM, et al: Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005;90:2855-2864
3. Netchine I, Azzi S, Houang M, et al: Partial primary deficiency of insulin-like growth factor (IGF)-I activity associated with IGF-1 mutation demonstrates its critical role in growth and brain development. J Clin Endocrinol Metab 2009;94:3913-3921
4. Camacho-Hubner C, Woods KA, Miraki-Moud F, et al: Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion. J Clin Endocrinol Metab 1999;84:1611-1616
5. Woods KA, Camacho-Hubner C, Bergman RN, et al: Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000;85:1407-1411
6. Saenger P, Czernichow P, Hughes I, Reiter EO: Small for gestational age: short stature and beyond. Endo Rev 2007;28:219-251
7. Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75: 73-82
8. Liu JP, Baker J, Perkins AS, et al: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-I) and type I IGF receptor (Igflr). Cell 1993;75:59-72
9. Laron Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentation of growth hormone-a new inborn error of metabolism? Isr J Med Sci 1966;2:152-155
10. David A, Hwa V, Metherell LA, et al: Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev 2011;32:472-497
11. Ayling RM, Ross R, Towner P, et al: A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 1997;16:13-14
12. Iida K, Takahashi Y, Kaji H, et al: Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab 1998;83:531-537
13. Derr MA, Aisenberg J, Fang P, et al: The growth hormone receptor (GHR) c.899dupC mutation functions as a dominant negative: insights into the pathophysiology of intracellular GHR defects. J Clin Endocrinol Metab 2011;96:E1896-E1904
14. Burren CP, Woods KA, Rose SJ, et al: Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome. Horm Res 2001;55:125-130
15. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J: Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15:369-390
16. Aalbers AM, Chin D, Pratt KL, et al: Extreme elevation of serum growth hormone-binding protein concentrations resulting from a novel heterozygous splice site mutation of the growth hormone receptor gene. Horm Res 2009;71:276-284
17. Derr MA, Fang P, Sinha SK, et al: A novel Y332C missense mutation in the intracellular domain of the human growth hormone receptor (GHR) does not alter STAT5b signaling: redundancy of GHR intracellular tyrosines involved in STAT5b signaling. Horm Res 2011;75:187-199
18. David A, Camacho-Hubner C, Bhangoo A, et al: An intronic growth hormone receptor mutation causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity phenotypes. J Clin Endocrinol Metab 2007;92:655-659
19. Kofoed EM, Hwa V, Little B, et al: Growthhormone insensitivity (GHI) associated with a STAT-5b mutation. N Engl J Med 2003;349:1139-1147
20. Hwa V, Nadeau K, Wit JM, Rosenfeld RG: STAT5b deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab 2011;25:61-75
21. Milward A, Metherell L, Maamra M, et al: Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after Box1, resulting in isolated failure of STAT5 signal transduction. J Clin Endocrinol Metab 2004;89:1259-1266
22. Tiulpakov A, Rubtsov P, Peterkova V, et al: A novel C-terminal growth hormone receptor (GHR) mutation results in impaired GHRSTAT5 but normal STAT3 signaling. J Clin Endocrinol Metab 2005;90:542-547
23. Nadeau K, Hwa V, Rosenfeld RG: STAT5b deficiency: An unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. J Pediatr 2011;158:701-708
24. Pugliese-Pires PN, Tonelli CA, Dora JM, et al: A novel STAT5B mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings. Eur J Endocrinol 2010;163:349-355
25. Janosi JBM, Ramsland PA, Mott MR, et al: The acid-labile subunit of the serum insulinlike growth factor-binding protein complexes. J Biol Chem 1999;274:23328-23332
26. Domene HM, Bengolea SV, Martinez AS, et al: Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004;350:570-577
27. Domene HM, Hwa V, Jasper HG, Rosenfeld RG: Acid-labile subunit (ALS) deficiency. Best Pract Res Clin Endocrinol Metab 2011;25:101-113
28. Klammt J, Kiess W, Pfaffle R: IGFIR mutations as cause of SGA. Best Pract Res Clin Endocrinol Metab 2011;25:191-206
29. Walenkamp MJE, van der Kamp HJ, Pereira AM, et al: A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the IGF-I receptor. J Clin Endocrinol Metab 2006;91: 3062-3070
30. Mohn A, Marcovecchio ML, de Giorgis T, et al: An insulin-like growth factor-I receptor defect associated with short stature and impaired carbohydrate homeostasis in an Italian pedigree. Horm Res Paediatr 2011;76:136-143
31. Binder G, Neuer K, Ranke MB, Wittekindt NE: PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 2005;90:5377-5381
32. Limal JM, Parfait B, Cabrol S, et al: Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 2006;91:300-306
33. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397
34. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
35. James C, Ugo V, le Couedic J-P, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148
36. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
37. Schubbert S, Zenker M, Rowe SL, et al: Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006;38:331-336
38. Niihori T, Aoki Y, Narumi Y, et al: Germline KRAS and BRAF mutations in cardiofacio-cutaneous syndrome. Nat Genet 2006;38:294-296
39. Rauen KA: HRAS and the Costello syndrome. Clin Genet 2007;71:101-108
40. Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al: Germline mutations in genes within the MAPK pathway cause cardiofacio-cutaneous syndrome. Science 2006;311:1287-1290
41. Roberts AE, Araki T, Swanson KD, et al: Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007;39:70-74
42. Tartaglia M, Pennacchio LA, Zhao C, et al: Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007;39:75-79.